Arcus Biosciences, Inc. (RCUS) Investor Relations Documents

Arcus Biosciences, Inc. (RCUS) investor relations documents from the company's IR site: 2 presentations, 7 press releases; latest deck 2026-05-05. Read in-app with summaries. First-party data.

DOWNLOAD PDF (OPENS IN NEW WINDOW): Arcus Biosciences 1Q26 corporate presentation highlighting ~$876M cash runway to 2H28, Phase 3 casdatifan enrollment in 1L RCC, and emerging I&I pipeline.

Investor relations documents — source: company IR site

Published	Type	Document
2026-06-09	Press release	Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
	Press release	Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
2026-05-05	Presentation	DOWNLOAD PDF (OPENS IN NEW WINDOW)
2026-02-28	Press release	Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in L
2026-01-14	Press release	Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
2026-01-10	Presentation	Presentation (opens in new window)
	Press release	New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated
	Press release	Arcus Biosciences to Participate in Two Upcoming Investor Conferences
	Press release	Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with

RCUS overview · RCUS earnings · RCUS financials · RCUS KPIs · RCUS documents · RCUS ownership · RCUS peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.